Mal-Val-Ala-PAB-N (SO2Me) -Exatecan

Mal-Val-Ala-PAB-N (SO2Me) -Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N (SO2Me) . Mal-Val-Ala-PAB-N (SO2Me) -Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer[1][2].

Product Specifications

CAS Number

[2575682-08-3]

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mal-val-ala-pab-n-so2me-exatecan.html

Purity

99.11

Solubility

DMSO : 100 mg/mL

Smiles

O=C(C=CC1=O)N1CCCCCC(N[C@@H](C(C)C)C(N[C@@H](C)C(NC(C=C2)=CC=C2COC(N(CCS(C)(=O)=O)COCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C84)=O)=O)=O)=O)=O

Molecular Formula

C56H65FN8O15S

Molecular Weight

1141.22

References & Citations

[1]Guo Q, et al., FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28. |[2]Liu N, et al., Preparation method of linker drug conjugate and intermediate thereof. CN116178386.